IL-10 and IL-12 (P70) Levels Predict the Risk of Covid-19 Progression in Hypertensive Patients: Insights From the BRACE-CORONA Trial.

Autor:	Moll-Bernardes R; D'Or Institute for Research and Education, Rio de Janeiro, Brazil., de Sousa AS; D'Or Institute for Research and Education, Rio de Janeiro, Brazil.; Evandro Chagas National Institute of Infectious Disease, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Macedo AVS; D'Or Institute for Research and Education, Rio de Janeiro, Brazil.; Hospital São Luiz Jabaquara, São Paulo, Brazil.; Santa Casa de São Paulo, São Paulo, Brazil., Lopes RD; D'Or Institute for Research and Education, Rio de Janeiro, Brazil.; Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, United States.; Brazilian Clinical Research Institute, São Paulo, Brazil., Vera N; Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Maia LCR; Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Feldman A; D'Or Institute for Research and Education, Rio de Janeiro, Brazil.; Hospital São Luiz Anália Franco, São Paulo, Brazil., Arruda GDAS; Hospital São Luiz São Caetano, São Caetano do Sul, Brazil., Castro MJC; Instituto de Microbiologia Paulo de Góes, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Pimentel-Coelho PM; Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., de Albuquerque DC; D'Or Institute for Research and Education, Rio de Janeiro, Brazil.; Cardiology Department, Rio de Janeiro State University, Rio de Janeiro, Brazil., de Paula TC; Hospital São Luiz Jabaquara, São Paulo, Brazil., Furquim TAB; Hospital Sino Brasileiro, Osasco, Brazil., Loures VA; Hospital São Luiz Anália Franco, São Paulo, Brazil., Giusti KGD; Hospital Villa Lobos, São Paulo, Brazil., de Oliveira NM; Hospital Villa Lobos, São Paulo, Brazil., De Luca FA; Hospital São Luiz Morumbi, São Paulo, Brazil., Kotsugai MDM; Hospital São Luiz Morumbi, São Paulo, Brazil., Domiciano RAM; Hospital São Luiz Anália Franco, São Paulo, Brazil., Santos MF; D'Or Institute for Research and Education, Rio de Janeiro, Brazil., de Souza OF; D'Or Institute for Research and Education, Rio de Janeiro, Brazil.; Hospital Copa Star, Rio de Janeiro, Brazil., Bozza FA; D'Or Institute for Research and Education, Rio de Janeiro, Brazil.; Evandro Chagas National Institute of Infectious Disease, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Luiz RR; D'Or Institute for Research and Education, Rio de Janeiro, Brazil.; Institute for Studies in Public Health-IESC, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Medei E; D'Or Institute for Research and Education, Rio de Janeiro, Brazil.; Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.; National Center for Structural Biology and Bioimaging, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2021 Jul 27; Vol. 8, pp. 702507. Date of Electronic Publication: 2021 Jul 27 (Print Publication: 2021).
DOI:	10.3389/fcvm.2021.702507
Abstrakt:	Background: Cardiovascular comorbidities such as hypertension and inflammatory response dysregulation are associated with worse COVID-19 prognoses. Different cytokines have been proposed to play vital pathophysiological roles in COVID-19 progression, but appropriate prognostic biomarkers remain lacking. We hypothesized that the combination of immunological and clinical variables at admission could predict the clinical progression of COVID-19 in hypertensive patients. Methods: The levels of biomarkers, including C-reactive protein, lymphocytes, monocytes, and a panel of 29 cytokines, were measured in blood samples from 167 hypertensive patients included in the BRACE-CORONA trial. The primary outcome was the highest score during hospitalization on the modified WHO Ordinal Scale for Clinical Improvement. The probability of progression to severe disease was estimated using a logistic regression model that included clinical variables and biomarkers associated significantly with the primary outcome. Results: During hospitalization, 13 (7.8%) patients showed progression to more severe forms of COVID-19, including three deaths. Obesity, diabetes, oxygen saturation, lung involvement on computed tomography examination, the C-reactive protein level, levels of 15 cytokines, and lymphopenia on admission were associated with progression to severe COVID-19. Elevated levels of interleukin-10 and interleukin-12 (p70) combined with two or three of the abovementioned clinical comorbidities were associated strongly with progression to severe COVID-19. The risk of progression to severe disease reached 97.5% in the presence of the five variables included in our model. Conclusions: This study demonstrated that interleukin-10 and interleukin-12 (p70) levels, in combination with clinical variables, at hospital admission are key biomarkers associated with an increased risk of disease progression in hypertensive patients with COVID-19. Competing Interests: RDL reports receiving grant support from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Sanofi, and Pfizer, and consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, Sanofi, and Portola. AM reports receiving consulting fees from Pfizer, Bayer, AstraZeneca, Novartis, Daiichi-Sankyo, Zodiac, Roche, and Janssen. AF reports receiving consulting fees from Pfizer, Bayer, Daiichi-Sankyo, Boehringer, and Servier. GA reports receiving consulting fees from Bayer, Pfizer, Servier, AstraZeneca, and Daichii Sankyo. DA reports receiving consulting fees from Boehringer Ingelheim, AstraZeneca, Bayer, and Servier. OS reports receiving grant support from Boehringer Ingelheim and consulting fees from Pfizer, Bayer, Daiichi-Sankyo, and Boehringer Ingelheim. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Moll-Bernardes, de Sousa, Macedo, Lopes, Vera, Maia, Feldman, Arruda, Castro, Pimentel-Coelho, de Albuquerque, de Paula, Furquim, Loures, Giusti, de Oliveira, De Luca, Kotsugai, Domiciano, Santos, de Souza, Bozza, Luiz and Medei.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu